MART-1 Antibody for IHC / Melanoma Antigen Immunohistochemistry Antibody [clone MSVA-900M] (V5893)

Catalog No.	Formulation	Size
V5893-100UG	Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide	100 ug
V5893-20UG	Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide	20 ug

Recombinant | MOUSE MONOCLONAL

Bulk quote request

Species Reactivity	Human
Format	Purified
Host	Mouse
Clonality	Recombinant Mouse Monoclonal
Isotype	Mouse IgG1, kappa
Clone Name	MSVA-900M
UniProt	Q16655
Localization	Endoplasmic reticulum membrane, Golgi apparatus, Melanosome, trans-Golgi network membrane
Applications	Immunohistochemistry (FFPE) : 1:100-1:200
Limitations	This MART-1 Antibody for IHC / Melanoma Antigen Immunohistochemistry Antibody is available for research use only.



MART-1 Antibody for IHC Tissue Microarray (TMA) multi-tissue expression. Immunohistochemistry analysis of MART-1 (MLANA) expression in FFPE human tissue microarray (TMA) sections using MART-1 Antibody for IHC clone MSVA-900M demonstrates selective cytoplasmic HRP-DAB brown staining in melanocytic cells and melanoma tumors, with minimal staining observed in non-melanocytic tissues. In cancer tissue arrays, strong staining highlights melanoma tumor cell populations, while surrounding stromal and epithelial components remain largely negative. The consistent staining pattern across TMA cores supports its use as a melanocytic lineage marker and aligns with established MLANA expression data.

Description

MART-1, also known as Melan A or MLANA, is a melanocyte-associated antigen involved in melanosome formation and pigment production and is widely expressed in normal melanocytes and melanocytic tumors. It is recognized as a key antigen associated with melanocytic differentiation and is commonly used as a marker for identifying melanoma and

related lesions. In immunohistochemistry, MART-1 is detected as cytoplasmic HRP-DAB brown staining in melanocytes and melanoma cells, providing a clear and reliable pattern for identifying melanocytic lineage in FFPE tissue sections. MART-1 Antibody for IHC is frequently used in studies of melanoma biology and tumor identification.

MART-1 antibody, also referred to as Melan A antibody or MLANA antibody in the literature, recognizes a cytoplasmic protein with highly restricted expression in melanocytic cells. This MART-1 Antibody for IHC is optimized for Tissue Microarray (TMA)-based immunohistochemistry, enabling high-throughput evaluation of melanocyte-associated antigen expression across diverse tissue panels. In normal tissue TMAs, staining is limited to melanocytes, while the majority of non-melanocytic tissues remain negative, reinforcing its specificity for melanocytic lineage detection.

In cancer tissue microarrays, MART-1 expression is strongly associated with melanoma, where diffuse cytoplasmic staining highlights tumor cells with melanocytic origin. This staining pattern enables clear visualization of tumor cell populations within complex tumor microenvironments and supports differentiation from non-melanocytic malignancies. The absence of staining in most epithelial and mesenchymal tumors further supports its lineage specificity.

Tissue Microarray (TMA) analysis allows direct comparison of MART-1 expression across a wide range of normal and cancer tissues under standardized conditions, demonstrating consistent and reproducible staining in melanocytic tumors with minimal background signal. Clone MSVA-900M provides clear and well-defined cytoplasmic staining across TMA cores, supporting its use in melanoma-focused tissue profiling and antigen-based studies. Observed staining patterns are consistent with established MLANA expression profiles and publicly available datasets such as the Human Protein Atlas.

This antibody targets MART-1 in research applications requiring reliable immunohistochemical detection of melanoma-associated antigens, making it well suited for studies of melanoma biology, tumor identification, and melanocytic differentiation.

This antibody is part of the Melan-A antibody collection, where additional MLANA/MART-1 antibodies for various applications can be explored.

This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.

Application Notes

1. Optimal dilution of the MART-1 Antibody for IHC / Melanoma Antigen Immunohistochemistry Antibody should be determined by the researcher.

2. This MART-1/Melanoma antigen recognized by T-cells 1 antibody is recombinantly produced by expression in human HEK293 cells.

3. Manual Protocol: Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121oC in pH 7.8 Target Retrieval Solution buffer. Apply the antibody at a dilution of 1:150 at 37oC for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer's directions.

Immunogen

Recombinant full-length hMART-1 protein was used as the immunogen for the MART-1/Melanoma antigen recognized by T-cells 1 antibody.

Storage

MART-1/Melanoma antigen recognized by T-cells 1 antibody with sodium azide - store at 2 to 8oC; antibody without sodium azide - store at -20 to -80oC.

Alternate Names

MART-1 antibody, MLANA antibody, Melan-A antibody, melanoma antigen recognized by T cells antibody, melanocyte marker antibody